OsolA., PrattR., and AltschuleM.D.: United States Dispensatory and Physicians' Pharmacology, 26th Ed., J. B. Lippincott Co., Philadelphia, pp. 815–818, 1967.
3.
WaitzJ. A., and WeinsteinM.: Recent Laboratory Studies with Gentamicin with Reference to Structure and Resistance, Med. J. Aust.1 (Suppl.): 19–25 (June 13) 1970.
4.
RileyH. D.: Clinical and Laboratory Evaluation of Gentamicin in Infants and Children, J. Infec. Dis.124 (Suppl.): 236–246 (Dec.) 1971.
5.
CoxC. E.: Gentamicin, a New Aminoglycoside Antibiotic: Clinical and Laboratory Studies in Urinary Tract Infections, J. Infec. Dis.119: 486–491 (Apr.-May) 1969.
6.
JacksonG. G., and RiffL. J.: Pseudomonas Bacteremia: Pharmacologic and Other Bases for Failure of Treatment with Gentamicin, J. Infec. Dis.124 (Suppl.): 185–191 (Dec.) 1971.
7.
CoxC. E.: Gentamicin, Med. Clin. N. Amer.54: 1305–1315 (Sept.) 1970.
8.
SnellingC. F.: Resistance of Gram-Negative Bacilli to Gentamicin, J. Infec. Dis.124 (Suppl.): 264–270 (Dec.) 1971.
9.
WeinsteinM. J.: Microbiologic Studies Related to Bacterial Resistance to Gentamicin, J. Infec. Dis.124 (Suppl.): 11–17 (Dec.) 1971.
10.
FinegoldS. M., and SutterV. L.: Susceptibility of Gram-Negative Anaerobic Bacilli to Gentamicin and Other Aminoglycosides, J. Infec. Dis.124 (Suppl.): 56–58 (Dec.) 1971.
11.
KabinsS. A.: R-Factor-Mediated Resistance to Gentamicin in a Clinical Isolate of Escherichia coli, J. Infec. Dis.124 (Suppl.) 65–67 (Dec.) 1971.
12.
ShulmanJ. A.: Colonization with Gentamicin-Resistant Pseudomonas aeruginosa, Pyocine Type 5, in a Burn Unit, J. Infec. Dis.124 (Suppl): 18–23 (Dec.) 1971.
13.
AbstonS.: Gentamicin for Septicemia in Patients with Burns, J. Infec. Dis.124 (Suppl.): 275–277(Dec.) 1971.
14.
MacMillanB. G.: Ecology of Bacteria Colonizing the Burned Patient Given Topical and Systemic Gentamicin Therapy: A Five-Year Study, J. Infec. Dis.124 (Suppl.): 278–286 (Dec.) 1971.
15.
KleinJ. O.: Gentamicin: Activity in Vitro and Observations in 26 Patients, Amer. J. Med. Sci.248: 528–544 (Nov.) 1964.
16.
RiffL.: Discussion. Session IV. Use in Clinical Syndromes, J. Infec. Dis.119: 529–530 (Apr.-May) 1969.
17.
MartinC. M.: Gram-Negative Rod Bacteremia, J. Infec. Dis.119: 506–517 (Apr.-May) 1969.
18.
NunneryA. W., and RileyH. D.: Gentamicin Clinical and Laboratory Studies in Infants and Children, J. Infec. Dis.119: 460–464 (Apr.-May) 1969.
19.
YoungL. S.: Gentamicin in the Treatment of Severe. Hospital-Acquired Infections, Trans. N.Y. Acad. Sci.29: 579–588 (Mar.) 1967.
20.
StratfordB. C., and DixsonS.: Results of Treatment of 104 Patients with Gentamicin, Med. J. Aust.1: 1107–1110 (May 22) 1971.
21.
HollowayW. J., and TaylorW. A.: Gentamicin and Kanamycin in the Treatment of Gram-Negative Sepsis: A Comparative Study, J. Infec. Dis.124 (Suppl.): 180–184 (Dec.) 1971.
22.
BodeyG. P.: Intravenous Gentamicin Therapy for Infections in Patients with Cancer, J. Infec. Dis.124 (Suppl.): 174–179 (Dec.) 1971.
23.
KleinJ. O.: Gentamicin in Serious Neonatal Infections: Absorption. Excretion and Clinical Results in 25 Cases, J. Infec. Dis.124 (Suppl.): 224–231 (Dec.) 1971.
24.
BrumfittW.: Clinical and Laboratory Studies with Carbenicillin. A New Penicillin Active Against Pseudomonas Pyocyanea, Lancet1: 1289–1293 (June 17), 1967.
25.
StandifordH. C.: Laboratory and Clinical Studies of Carbenicillin against Gram-Negative Bacilli, Antimicrob. Agents and Chemother. — 1968, pp. 286–291, 1969.
26.
SmithC. B.: Use of Gentamicin in Combination with Other Antibiotics, J. Infec. Dis.119: 370–377 (Apr.-May) 1969.
27.
SonneM., and JawetzE.: Combined Action of Carbenicillin and Gentamicin on Pseudomonas Aeruginosa In Vitro, Appl. Microbiol.17: 895–896 (June) 1969.
28.
EickhoffT. C.: In Vitro Effects of Carbenicillin Combined with Gentamicin or Polymyxin B against Pseudomonas Aeruginosa, Appl. Microbiol.18: 469–473 (Sept.) 1969.
29.
SutherlandR.: Alpha-Carboxy-3-Thienylmethyl Penicillin (RRL2288), a New Semisynthetic Penicillin - In VitroEvaluation, Antimicrob. Agents Chemother. — 1970, pp. 390–95, 1971.
30.
PhairJ. P., et al.: In Vitro Susceptibility of Pseudomonas Aeruginosa to Carbenicillin and The Combination of Carbenicillin and Gentamicin, Appl. Microbiol.18: 303–306 (Sept.) 1969.
31.
NunneryA. W.: Carbenicillin: In Vitro Synergism and Combined Therapy, J. Infec. Dis.122 (Suppl.): 578–583 (Sept.) 1970.
32.
KasterskyJ.: Antimicrobial Activity of the Carbenicillin/Gentamicin Combination Against Gram-Negative Bacilli, Amer. J. Med. Sci.260: 373–380 (Dec.) 1970.
33.
WatanakunakornC.: Penicillin Combined with Gentamicin or Streptomycin: Synergism against Enterococci, J. Infec. Diseases.124: 581–585 (Dec.) 1971.
34.
RosdahlN., and ThomsenV. F.: In Vitro Activity of Gentamicin, Alone and in Combination with Other Antibiotics, Acta. Path. Microbiol. Scand.79: 333–342, 1971.
35.
MoelleringR. C.: Synergy of Penicillin and Gentamicin Against Enterococci, J. Infec. Dis.124 (Suppl.): 207–209 (Dec.) 1971.
36.
SmithI. M.: Supplemental Antibiotics to Enhance the Action of Gentamicin in Pseudomonas and Mixed Infections, J. Infec. Dis.124 (Suppl.): 198–201 (Dec.) 1971.
37.
KlasterskyJ.: Bacteriological and Clinical Activity of the Ampicillin/Gentamicin and Cephalothin/Gentamicin Combinations, Amer. J. Med. Sci.262: 283–290 (Nov.) 1971.
38.
YoungL. S.: Gentamicin; Clinical Use with Carbenicillin and In Vitro Studies with Recent Isolates of Pseudomonas Aeruginosa, J. Infec. Dis.124 (Suppl.): 202–206 (Dec.) 1971.
39.
KlasterskyJ.: Effect of the Combination of Gentamicin and Carbenicillin on the Bactericidal Activity of Serum, J. Infec. Dis.125: 183–186 (Feb.) 1972.
40.
RodriguezV.: Therapy of Infections with the combination of Carbenicillin and Gentamicin, Antimicrob. Agents and Chemother.-1969, pp. 386–390, 1970.
41.
MarksM. I.: Carbenicillin and Gentamicin: Pharmacologic Studies in Patients with Cystic Fibrosis and Pseudomonas Pulmonary Infections, J. Pediat.79: 822–823 (Nov.) 1971.
42.
YuceK., and van RooyenC. E.: Carbenicillin and Gentamicin in the Treatment of Pseudomonas Aeruginosa Infections, Can. Med. Assoc. J.105: 919–922 (Nov. 6) 1971.
43.
KlasterskyJ.: Evaluation of Gentamicin with Carbenicillin in Infections Due to Gram-Negative Bacilli. Curr. Ther. Res.13: 174–181 (Mar.) 1971.
44.
HerrellW. E.: Carbenicillin and Gentamicin in Suspected Sepsis, Clin. Med.78: 10–11 (Aug.) 1971.
45.
SmithC. B., et al.: In-Vitro Activity of Carbenicillin and Results of Treatment of Infections Due to Pseudomonas With Carbenicillin Singly and in Combination with Gentamicin, J. Infec. Dis.122: (Suppl.): 14–25 (Sept.) 1970.
46.
AndrioleV. T.: Synergy of Carbenicillin and Gentamicin in Experimental Infections with Pseudomonas, J. Infec. Dis.124 (Suppl.): 46–55 (Dec.) 1971.
47.
MclaughlinJ. E., and ReevesD. S.: Clinical and Laboratory Evidence for Inactivation of Gentamicin by Carbenicillin, Lancet1: 261–264 (Feb.) 1971.
48.
WaitzJ. A.: Biological Aspects of the Interaction Between Gentamicin and Carbenicillin, J. Antibiot.25: 219–225 (Apr.) 1972.
49.
WintersR. E.: Combined Use of Gentamicin and Carbenicillin, Ann. Intern. Med.75: 925–927 (Dec.) 1971.
50.
NooneP., and PattisonJ. R.: Therapeutic Implications of Interaction of Gentamicin and Penicillins, Lancet2: 575–578 (Sept. 11) 1971.
51.
ArcieriG. M.: Clinical Research Experience with Gentamicin. Incidence of Adverse Reactions, Med. J. Aust.1 (Suppl.): 30–34 (June 13) 1970.
52.
LynfieldY. L.: Allergic Contact Sensitization to Gentamicin, N.Y. State J. Med.70: 2235–2236 (Sept.) 1970.
53.
StoneH. H., and KolbL.: Gentamicin Sulfate in the Treatment of Extra-Urinary Infections Due to Gram-Negative Bacteria, S. J. Med.60: 142–144 (Feb.) 1967.
54.
FalcoF. G.: Nephrotoxicity of Aminoglycosides and Gentamicin, J. Infec. Dis.119: 406–409 (Apr.-May) 1969.
SchultzeR. G.: Possible Nephrotoxicity of Gentamicin, J. Infec. Dis.124 (Suppl.): 145–7 (Dec.) 1971.
57.
JacksonG. G., and ArcieriG.: Ototoxicity of Gentamicin in Man; A Survey and Controlled Analysis of Clinical Experience in the United States, J. Infec. Dis.124 (Suppl.): 130–137 (Dec.) 1971.
58.
WilfertJ. M.: Renal Insufficiency Associated with Gentamicin Therapv, J. Infec. Dis.124 (Suppl.): 148–153 (Dec.) 1971.
59.
KahnT., and SteinR. M.: Gentamicin and Renal Failure, Lancet.1: 498 (Feb.) 1972.
60.
IgarashiM.: Experimental Ototoxicity of Gentamicin in Squirrel Monkeys, J. Infec. Dis.124 (Suppl.): 114–124 (Dec.) 1971.
61.
Koch-WeserJ.: Adverse Effects of Sodium Colistimethate. Manifestations and Specific Reaction Rates During 317 Courses of Therapy, Ann. Intern. Med.72: 857–868 (June) 1970.
62.
BobrowS. N.: Anuria and Acute Tubular Necrosis Associated with Gentamicin and Cephalothin, J. Amer. Med. Assoc.222: 1546–1547 (Dec.) 1972.
63.
BrazilO. V., and FranceschiJ. P.: The Neuromuscular Blocking Action of Gentamicin, Arch. Int. Pharmacodyn.179: 65–77, 1969.
64.
BrazilO. V., and FranceschiJ. P.: The Nature of Neuromuscular Block Produced by Neomycin and Gentamycin, Arch. Int. Pharmacodyn.179: 78–86, 1969.
65.
BarnettA., and AckermanE.: Neuromuscular Blocking Activity of Gentamicin in Cats and Mice, Arch. Int. Pharmacodyn.181: 109–117, 1969.
66.
WarnerW. A., and SandersE.: Neuromuscular Blockade Associated with Gentamicin Therapy, J. Amer. Med. Assoc.215: 1153–1154 (Feb. 15) 1971.
67.
NewmanR. L., and HoltR. J.: Gentamicin in Pediatrics. I. Report on Intrathecal Gentamicin, J. Infec. Dis.124 (Suppl.): 254–256 (Dec.) 1971.
68.
MathiesA. W.: Gentamicin in the Treatment of Meningitis, J. Infec. Dis.124 (Suppl.): 249–253 (Dec.) 1971.
69.
VacekV.: Penetration of Antibiotics into the Cerebrospinal Fluid in Inflammatory Conditions. III. GentamicinInt. J. Clin. Pharmacol.2: 277–279 (July) 1969.
70.
YoshiokaH.: Placental Transfer of Gentamicin, J. Pediat.80: 121–123 (Jan.) 1972.
71.
GoldenB., and CoppelS. P.: Ocular Tissue Absorption of Gentamicin, Arch. Ophthal.84: 792–796 (Dec.)
72.
RiffL. J., and JacksonG. G.: Pharmacology of Gentamicin in Man, J. Infec. Dis.124 (Suppl.): 98–105 (Dec.) 1971.
73.
AltmannG.: Blood Levels of Ampicillin, Kanamycin and Gentamicin in the Uremic Patient, Israel J. Med. Sci.6: 683–690 (Nov.-Dec.) 1970.
74.
WintersR. E.: Relation Between Dose and Levels of Gentamicin in Blood, J. Infec. Dis.124 (Suppl.): 90–95 (Dec.) 1971.
75.
McCrackenG. H., and JonesL. G.: Gentamicin in the Neonatal Period, Amer. J. Dis. Child.120: 524–533 (Dec.) 1970.
76.
GyselynckA. M.: Pharmacokinetics of Gentamicin: Distribution and Plasma and Renal Clearances, J. Infec. Dis.124 (Suppl.): 70–76 (Dec.) 1971.
77.
BerganT.: Renal Excretion of Gentamicin in Chronic Pyelonephritis, Acta. Med. Scand.189: 1–5, 1971.
78.
BerganT.: Influence of Probenecid on Gentamicin Pharmacokinetics, Acta. Med. Scand.191: 221–224, 1972.
79.
von KobyletzkiD.: Zur Pharmcaokinetik von Gentamicin in Serum und Harn, Med. Klin.64: 1497–1502 (Aug. 22) 1969.
80.
DumeT.: Pharmacokinetics of Gentamicin Sulfate in Normal Subjects and in Patients with Terminal Renal Failure, Duetsch. Med. Wschr.96: 734–41 (Apr. 23) 1971.
DarrellJ. H., and WaterworthP. M.: Dosage of Gentamicin for Pseudomonas Infections, Brit. Med. J.2: 535–537 (May 27) 1967.
83.
GingellJ. C., and WaterworthP. M.: Dose of Gentamicin in Patients with Normal Renal Function and Renal Impairment, Brit. Med. J.2: 19–22 (Apr. 6) 1968.
84.
McHenryM. C.: Gentamicin Dosage for Renal Insufficiency. Adjustments Based on Endogenous Creatinine Clearance and Serum Creatinine Concentration, Ann. Intern. Med.74: 192–197 (Feb.) 1971.
85.
CutlerR. E.: Correlation of Serum Creatinine Concentration and Gentamicin Half-Life, J. Amer. Med. Ass.219: 1037–1041 (Feb. 21) 1972.
86.
ChanR. A.: Gentamicin Therapy in Renal Failure: A Monogram for Dosage, Ann. Intern. Med.76: 773–778 (May) 1972.
87.
ChisholmG. D.: Distribution and Dosage of Antibacterial Agents in Patients with Normal and Impaired Renal Function, Med. J. Aust.1 (Suppl.) 25–29 (June 13) 1970.
88.
GyselynckA. M.: Gentamycin Pharmacokinetics: Distribution Volume, Renal and Plasma Clearance in Normal Subjects and Renal Insufficiency, Clin Res.19: 183 (Jan.) 1971.
89.
CurtisJ. R.: Parenteral Administration of Gentamicin in Renal Failure; Patients Undergoing Intermittent Hemodialysis, Brit. Med. J.2: 537–539 (May 27) 1967.
90.
GaryN. E.: Peritoneal Clearance and Removal of Gentamicin, J. Infec. Dis.124 (Suppl.): 96–7 (Dec.) 1971.
BunnP. A.: Kanamycin, Med. Clin. N. Amer.54: 1245–1256 (Sept.) 1970.
114.
GoodR. G., and JohnsonG. H.: The Placental Transfer of Kanamycin During Late Pregnancy, Obstet. Gynecol.38: 60–62 (July) 1971.
115.
PindellM. H.: Pharmacology of Kanamycin—A Review and New Developments, Ann. N.Y. Acad. Sci.132: 805–810 (June 14) 1966.
116.
SimonH. J., and AxlineS. G.: Clinical Pharmacology of Kanamycin in Premature Infants, Ann. N.Y. Acad. Sci.132: 1020–1025 (June 14) 1966.
117.
EichenwaldH. F.: Some observations on Dosage and Toxicity of Kanamycin in Premature and Full-Term Infants, Ann. N.Y. Acad. Sci.132: 984–991 (June 14) 1966.
118.
FinlandM.: Summary on the Conference on Kanamycin; Appraisal after Eight Years of Clinical ApplicationAnn. N.Y. Acad. Sci.132: 1045–1090 (June 14) 1966.
119.
BatesT. H.: Kanamycin Administration in Patients with Impaired Renal Function, Clin. Res13: 77 (Jan.) 1965.
120.
SorensenA. W. S.: A Correlation Between Renal Function and Serum Half-Life of Kanamycin and Its Application to Dosage Adjustment, Postgrad. Med. J.43 (Suppl.): 37–43 (May) 1967.
121.
CutlerR. E., and OrmeB. M.: Correlation of Serum Creatinine Concentration and Kanamycin Half-Life. Therapeutic Implications, J. Amer. Med. Ass.209: 539–542 (July 28) 1969.
122.
OrmeB. M., and CutlerR. E.: The Relationship Between Kanamycin Pharmacokinetics: Distribution and Renal Function, Clin. Pharmacol. Ther.10: 543–550 (July-August) 1969.
123.
MontalvoJ. M., and SmithM. S.: Peritoneal Dialysis in the Treatment of Kanamycin Overdose, S. Med. J.62: 1559–1560 (Dec.) 1969.
124.
GreenbergL. H., and MomarvA.: Audiotoxicity and Nephrotoxicity Due to Orally Administered Neomycin, J Amer. Med. Assoc.194: 827–828 (Nov. 15) 1965.
125.
CampanelliP. A.: Hearing Loss in a Child Following Neomycin Irrigation. Report of a Case, Med. Ann. D.C.35: 541–543 (Oct.) 1966.
126.
BellR. W.: Respiratory Failure Following Intramural Bowel Injection of Neomycin, Med. Ann. D.C.35: 603–604 (Nov.) 1966.
127.
RubenR. J., and DalyJ. E.: Neomycin Ototoxicity and Nephrotoxicity. A Case Report Following Oral Administration, Laryngoscope78: 1734–1737 (Oct.) 1968.
128.
KellyD. R.: Deafness after Topical Neomycin Wound Irrigation, New Eng. J. Med.280: 1338–1339 (June 12) 1969.
129.
KalbianV. V.: Deafness Following Oral Use of Neomycin, S. Med. J.65: 499–501 (Apr.) 1972.
130.
BerkD. P., and ChalmersT.: Deafness Complicating Antibiotic Therapy of Hepatic Encephalopathy, Ann. Intern. Med.73: 393–396 (Sept.) 1970
131.
WaisbrenB. A., and SpinkW. W.: Clinical Appraisal of Neomycin, Ann. Intern. Med.33: 1099–1119 (Nov.) 1950.
132.
FaloonW. W.: Effect of Neomycin and Kanamycin upon Intestinal Absorption, Ann. N.Y. Acad. Sci.132: 879–887 (June 14) 1966.
133.
KeuschG. T.: Neomycin Enteropathy in Man, Clin. Res.15: 237 (Apr.) 1967.
AchordJ. L.: Neomycin-Induced Malabsorption in Fasting Patients, Gastroenterol.56: 1244 June 1969.
136.
GordonS. J.: Studies of Malabsorption and Calcium Excretion Induced by Neomycin Sulfate. Effect of Intestinal Site, Bile Salt and Pancreatic Enzymes, J. Amer. Med. Ass.204: 129–134 (Apr. 8) 1968.
137.
FaloonW. W., and ChadosR. B.: Vitamin B12 Absorption Studies Using Colchicine, Neomycin and Continuous Co57 B12 Administration, Gastroenterol.56: 1251 (June) 1969.
138.
LindenbaumJ.: Impairment of Digoxin Absorption by Neomycin, Clin. Res.20: 410 (Apr.) 1972.
139.
KirtonV., and Munro-AshmanD.: Contact Dermatitis from Neomycin and Framycetin, Lancet1: 138–139 (Jan. 16) 1965.
140.
JensenO. C.: Neomycin Contact Dermatitis Superimposed on Otitis Externa, J. Amer. Med. Ass.195: 131–133 (Jan. 10) 1966.
141.
HjorthN., and ThomsenK.: Differences in the Sensitizing Capacity of Neomycin in Creams and Ointments, Brit. J. Derm.80: 163–169 (Mar.) 1968.
142.
LalD.: Intestinal Microflora in Patients with Alcoholic Cirrhosis; Urea-Splitting Bacteria and Neomycin Resistance, Gastroenterol62: 275–279 (Feb.) 1972.
143.
PanzerJ. D., and EpsteinW. L.: Percutaneous Absorption Following Topical Application of Neomycin, Arch. Derm.102: 536–539 (Nov.) 1970.
144.
HerdJ. K.: Ototoxicity of Topical Neomycin Augmented by DMSO, Ped.40: 905–907 (Nov.) 1967.
145.
KuninC. M.: Absorption of Orally Administered Neomycin and Kanamycin, New Eng. J. Med.262: 380–385 (Feb. 25) 1960.
146.
LastP. M., and SherlockS.: Systemic Absorption of Orally Administered Neomycin in Liver Disease, New Eng. J. Med.262: 385–389 (Feb. 25) 1960.
147.
BreenK. J.: Neomycin Absorption in Man. Studies of Oral and Enema Administration and Effect of Intestinal Ulceration, Ann. Intern. Med.76: 211–218 (Feb.) 1972.
148.
AxlineS. G.: Clinical Pharmacology of Antimicrobials in Premature Infants. Ampicillin, Methicillin, Oxacillin, Neomycin and Colistin, Ped.39: 97–110 (Jan.) 1967.
149.
LevyG., and JuskoW. J.: Factors Affecting the Absorption of Riboflavin in Man, J. Pharm. Sci.55: 285–289 (March) 1966.
150.
MayersohnM.: Ascorbic Acid Absorption in Man Pharmacokinetic Implications, Europ. J. Pharmacol.19: 140–142, 1972.
151.
BorgstromB.: Lymphatic Transport of Cholesterol in the Human Being. Effect of Dietary Cholesterol, Scand. J. Clin. Lab. Invest.26: 227–235, 1970.
152.
KrumlorskyF. A.: Dialysis in Treatment of Neomycin Overdosage, Ann. Intern. Med.74: 443–446 (Mar.) 1972.
153.
BerteS. J.: Isoniazid, Para-Aminosalicylic Acid and Streptomycin Intolerance in 1,744 Patients. An Analysis of Reactions to Single Drugs and Drug Group Plus Data on Multiple Reactions, Type and Time of Reactions and Desensitization, Amer. Rev. Resp. Dis.90: 593–606 (Oct.) 1964.
154.
SchwartzW. S.: Capreomycin Compared with Streptomycin in Original Treatment of Pulmonary Tuberculosis, XVI. Amer. Rev. Resp. Dis.94: 858–864 (Dec.) 1966.
155.
BobrowitzT. D.: Ethambutol Compared to Streptomycin in Original Treatment of Advanced Pulmonary Tuberculosis, Chest.60: 14–21 (July) 1971.
156.
BarlowM. B., and GroesbeckA.: Apparent Potentiation of Neuromuscular Block by Antibiotics, S. Afr. Med. J.40: 135–136 (Feb 12) 1966.
157.
RobinsonG. C., and CambonK. G.: Hearing Loss in Infants of Tuberculous Mothers Treated with Streptomycin during Pregnancy, New Eng. J. Med.271: 949–951 (Oct. 29) 1964.
158.
ConwayN., and BirtB. D., Streptomycin in Pregnancy: Effect on the Foetal Ear, Brit. Med. J.2: 260–263 (July 31) 1965.
159.
KuninC. M., and FinlandM.: Persistance of Antibiotics in Blood of Patients with Acute Renal Failure. III. Penicillin, Streptomycin, Erythromycin and Kanamycin, J. Clin. Invest.38: 1509–1519 (Sept.) 1959.
160.
KuninC. M.: A Guide to Use of Antibiotics in Patients with Renal Disease. A Table of Recommended Doses and Factors Governing Serum Levels, Ann. Intern. Med.67: 151–158 (July) 1967.
161.
EdwardsK. D. G., and WhyteH. M.: Streptomycin Poisoning in Renal Failure, Brit. Med. J.1: 752–754 (March 21) 1959.
162.
KuninC. M., and FinlandM.: Restrictions Imposed on Antibiotic Therapy by Renal Failure, Arch. Intern. Med.104: 1030–1050 (Dec.) 1959.
163.
GiustiD. L., and HaytonW. L.: Dosage Regimen Adjustments in Renal Impairment, Drug Intell. Clin. Pharm.7: 382–387 (Sept.) 1973.